Seamus Mulligan, Director at Jazz Pharmaceuticals plc (JAZZ), sold 50,000 shares at $179.04 ($8.7M) on 2015-03-25, disclosed to the SEC on 2015-03-27.
Scheduled sale ($8.7M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $172.13 | 3,455 | $595K | 6.8% |
| 2 | $173.00 | 13,801 | $2.4M | 27.4% |
| 3 | $173.82 | 10,977 | $1.9M | 21.9% |
| 4 | $174.87 | 8,171 | $1.4M | 16.4% |
| 5 | $176.07 | 4,300 | $757K | 8.7% |
| 6 | $177.08 | 4,300 |
| $761K |
| 8.7% |
| 7 | $178.13 | 4,321 | $770K | 8.8% |
| 8 | $179.04 | 200 | $36K | 0.4% |
| 9 | $181.80 | 475 | $86K | 1.0% |
| Total | $174.59 avg | 50,000 | $8.7M | 100% |
| Filing → |
| JAZZ | BUY | 2018-11-19 | $14.2M | — | Filing → |
| JAZZ | SELL | 2016-08-26 | $6.0M | — | Filing → |
| JAZZ | SELL | 2016-05-26 | $8.2M | — | Filing → |